|
|
| Line 1: |
Line 1: |
| [[Image:2jbu.jpg|left|200px]] | | {{Seed}} |
| | [[Image:2jbu.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
| Line 9: |
Line 10: |
| {{STRUCTURE_2jbu| PDB=2jbu | SCENE= }} | | {{STRUCTURE_2jbu| PDB=2jbu | SCENE= }} |
|
| |
|
| '''CRYSTAL STRUCTURE OF HUMAN INSULIN DEGRADING ENZYME COMPLEXED WITH CO-PURIFIED PEPTIDES.'''
| | ===CRYSTAL STRUCTURE OF HUMAN INSULIN DEGRADING ENZYME COMPLEXED WITH CO-PURIFIED PEPTIDES.=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| Insulin-degrading enzyme (IDE) is a zinc metalloprotease that hydrolyzes amyloid-beta (Abeta) and insulin, which are peptides associated with Alzheimer disease (AD) and diabetes, respectively. Our previous structural analysis of substrate-bound human 113-kDa IDE reveals that the N- and C-terminal domains of IDE, IDE-N and IDE-C, make substantial contact to form an enclosed catalytic chamber to entrap its substrates. Furthermore, IDE undergoes a switch between the closed and open conformations for catalysis. Here we report a substrate-free IDE structure in its closed conformation, revealing the molecular details of the active conformation of the catalytic site of IDE and new insights as to how the closed conformation of IDE may be kept in its resting, inactive conformation. We also show that Abeta is degraded more efficiently by IDE carrying destabilizing mutations at the interface of IDE-N and IDE-C (D426C and K899C), resulting in an increase in Vmax with only minimal changes to Km. Because ATP is known to activate the ability of IDE to degrade short peptides, we investigated the interaction between ATP and activating mutations. We found that these mutations rendered IDE less sensitive to ATP activation, suggesting that ATP might facilitate the transition from the closed state to the open conformation. Consistent with this notion, we found that ATP induced an increase in hydrodynamic radius, a shift in electrophoretic mobility, and changes in secondary structure. Together, our results highlight the importance of the closed conformation for regulating the activity of IDE and provide new molecular details that will facilitate the development of activators and inhibitors of IDE.
| | The line below this paragraph, {{ABSTRACT_PUBMED_17613531}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 17613531 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_17613531}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
| Line 34: |
Line 38: |
| [[Category: Protease]] | | [[Category: Protease]] |
| [[Category: Zinc]] | | [[Category: Zinc]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 08:39:40 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 06:02:56 2008'' |